Morgan Stanley analyst Tejas Savant maintained a Buy rating on 10x Genomics (TXG – Research Report) today and set a price target of $26.00. The ...
Full Year 2024 Results Key Financial Results Revenue: US$610.8m (down 1.3% from FY ...
Barclays lowered the firm’s price target on 10x Genomics (TXG) to $15 from $18 and keeps an Overweight rating on the shares.Maximize Your ...
13h
Hosted on MSNLeerink Partners Downgrades 10x Genomics (TXG)Fintel reports that on February 13, 2025, Leerink Partners downgraded their outlook for 10x Genomics (NasdaqGS:TXG) from ...
Genomics reported a Q4 EPS loss of $(0.40), missing estimates, while revenue declined 10% year over year. Analysts lowered price targets amid profitability concerns.
Q4 2024 Earnings Call Transcript February 12, 2025 10x Genomics, Inc. misses on earnings expectations. Reported EPS is $-0.4 ...
PLEASANTON, Calif. (AP) — PLEASANTON, Calif. (AP) — 10x Genomics Inc. (TXG) on Wednesday reported a loss of $49 million in its fourth quarter. The Pleasanton, California-based company said it had a ...
After the National Institutes of Health (NIH) announced late Friday that it would be following a Trump administration ...
Check the time stamp on this data. Updated AI-Generated Signals for 10x Genomics Inc. (TXG) available here: TXG. Type a few symbols and Take a Trial. The signals for these will appear immediately on ...
We recently compiled a list of the Cathie Wood’s Stock Portfolio: 2025 Stock Picks. In this article, we are going to take a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results